×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
LON:PRM

Proteome Sciences Share Forecast, Price & News

GBX 3.60
0.00 (0.00%)
(As of 07/4/2022 12:00 AM ET)
Add
Compare
Today's Range
3.44
3.60
50-Day Range
3.41
4.45
52-Week Range
3.20
7.50
Volume
N/A
Average Volume
290,825 shs
Market Capitalization
£10.63 million
P/E Ratio
41.00
Dividend Yield
N/A
Price Target
N/A

Proteome Sciences MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.69 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive PRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter.

Proteome Sciences logo

About Proteome Sciences (LON:PRM) Stock

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

PRM Stock News Headlines

Proteome Sciences : Price Monitoring Extension
Proteome Sciences : AGM Statement
Proteome Sciences : Result of AGM
Proteome Sciences PLC
Proteome Sciences PLCShs Stock , PMSNF
PROTEOME SCIENCES PLC Registere (PI2.SG)
See More Headlines

Industry, Sector and Symbol

Industry
Medical Laboratories & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
24
Year Founded
N/A

Company Calendar

Last Earnings
8/10/2020
Today
7/04/2022

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£5.13 million
Cash Flow
GBX 0.80 per share
Book Value
GBX (0.90) per share

Miscellaneous

Free Float
N/A
Market Cap
£10.63 million
Optionable
Not Optionable
Beta
N/A














Proteome Sciences Frequently Asked Questions

How has Proteome Sciences' stock performed in 2022?

Proteome Sciences' stock was trading at GBX 5.13 at the beginning of the year. Since then, PRM shares have decreased by 29.8% and is now trading at GBX 3.60.
View the best growth stocks for 2022 here
.

How were Proteome Sciences' earnings last quarter?

Proteome Sciences plc (LON:PRM) posted its earnings results on Monday, August, 10th. The company reported ($0.17) earnings per share for the quarter.
View Proteome Sciences' earnings history
.

Who are Proteome Sciences' key executives?

Proteome Sciences' management team includes the following people:
  • Dr. Mariola Sohngen, CEO & Exec. Director (Age 61, Pay $258k)
  • Dr. Ian H. Pike, Chief Scientific Officer & Exec. Director
  • Mr. Richard Paul Dennis, Chief Commercial Officer & Exec. Director (Age 63, Pay $225k)
  • Mr. Stefan Fuhrmann, Fin. Director
  • Mr. Glenn Barney, VP of Sales & Marketing
  • Victoria Birse, Company Sec.

What other stocks do shareholders of Proteome Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteome Sciences investors own include ValiRx (VAL), boohoo group (BOO), Mondi (MNDI), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), Quanterix (QTRX), Centrica (CNA), CyanConnode (CYAN) and Eckoh (ECK).

What is Proteome Sciences' stock symbol?

Proteome Sciences trades on the London Stock Exchange (LON) under the ticker symbol "PRM."

How do I buy shares of Proteome Sciences?

Shares of PRM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Proteome Sciences' stock price today?

One share of PRM stock can currently be purchased for approximately GBX 3.60.

How much money does Proteome Sciences make?

Proteome Sciences (LON:PRM) has a market capitalization of £10.63 million and generates £5.13 million in revenue each year.

How many employees does Proteome Sciences have?

Proteome Sciences employs 24 workers across the globe.

How can I contact Proteome Sciences?

Proteome Sciences' mailing address is Hamilton House, Mabledon Place, LONDON, WC1H 9BB, United Kingdom. The official website for Proteome Sciences is www.proteomics.com. The company can be reached via phone at +44-20-70432116.

This page (LON:PRM) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.